Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 1 6Phase 2 5Phase 3 3

Status

Active not recruiting 3Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 6CNS 1

Conditions

Multiple Myeloma 6Recurrence 1Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × iberdomide × 90 days × Clear all
NCT05583617 2026-06-03

PLYCOM

Hoffmann-La Roche

Phase 1/2 Recruiting
200 enrolled
Plasma cell

Multiple Myeloma

NCT05434689 2026-06-01

COMMANDER

University of Alabama at Birmingham

Phase 1/2 Active not recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT07601100 2026-06-01

IsaIberVD

Dana-Farber Cancer Institute

Phase 1/2 Not yet recruiting
88 enrolled
Plasma cell

Multiple Myeloma

NCT05392946 2026-04-21

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Mayo Clinic

Phase 1/2 Active not recruiting
49 enrolled
Plasma cell

Multiple Myeloma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06232044 2026-03-25

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Alliance for Clinical Trials in Oncology

Phase 1/2 Recruiting
88 enrolled
Plasma cell

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Celgene

Phase 1/2 Active not recruiting
466 enrolled 57 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡